Acelyrin: advancing in-licensed assets for immunology

With its first in-licensed asset poised for clinical development in at least three immunology indications, Acelyrin has won the backing of a long roster of VCs and crossover investors in a $250 million series B round, setting up the biotech to acquire rights to more programs.

Launched in December 2020 with an investment from Los Angeles-based Westlake Village BioPartners, Acelyrin Inc. said Tuesday it is advancing clinical development of IL-17A inhibitor izokibep (ABY-035) to treat uveitis, axial spondyloarthritis and hidradenitis suppurativa. Acelyrin has gained izokibep’s rights in most of the world under a deal with Swedish biotech Affibody AB...